Johnson & Johnson is easily the largest big pharma employer, and on certain metrics outstrips smaller rivals.
Vir’s tie-up with Glaxo leads recent deal activities aiming to treat the new coronavirus.
Antivirals, anti-interleukins and vaccines take centre stage in clinical trial efforts to tackle the coronavirus pandemic.
The deal between Sangamo and Biogen marks another endorsement of a gene-editing technology that many had written off years ago.
Six months after evobrutinib’s two pivotal multiple sclerosis studies started enrolment, their comparator cohorts are overhauled.
Clinical results this year from companies including Roche, Biogen and Sanofi should show whether new drug classes can arrest the development of Parkinson’s disease.
Drug developers have directed almost half of their dealmaking firepower at oncology projects over the past five years, with cardiovascular a distant second.
A fresh blow to the beta-amyloid hypothesis has not rattled Biogen's supporters, but Lilly shareholders were apparently hoping for more.
Investors betting on the Principia short thesis face up to a clinical trial success that might not be what it seems.